Difference between revisions of "Estramustine (Emcyt)"
Jump to navigation
Jump to search
(updated content) |
Warner-admin (talk | contribs) m (Text replacement - "chemocare.com/chemotherapy/drug-info" to "chemocare.com/druginfo") |
||
| (17 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
| − | Class/mechanism: Nornitrogen mustard (similar to [[Mechlorethamine (Mustargen)|mechlorethamine]]) linked to estradiol. | + | Class/mechanism: Nornitrogen mustard (similar to [[Mechlorethamine (Mustargen)|mechlorethamine]]) linked to estradiol. The estradiol component helps the drug to be preferentially delivered to estrogen receptor-positive cells. The mustard component serves as an alkylator and causes DNA crosslinks. Treatment may result in elevated plasma levels of estradiol.<ref name="insert">[http://www.pfizer.com/files/products/uspi_emcyt.pdf Estramustine (Emcyt) package insert]</ref><ref>[[:File:Estramustine.pdf | Estramustine (Emcyt) package insert (locally hosted backup)]]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| Line 12: | Line 10: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://chemocare.com/ | + | *[http://www.pfizer.com/files/products/uspi_emcyt.pdf Estramustine (Emcyt) package insert]<ref name="insert"></ref> |
| + | *[https://chemocare.com/druginfo/estramustine.aspx Estramustine (Emcyt) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/estramustine.aspx Estramustine (Emcyt) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/estramustine-patient-drug-information Estramustine (Emcyt) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/estramustine-patient-drug-information Estramustine (Emcyt) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/estramustine-patient-drug-information Estramustine (Emcyt) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/estramustine-patient-drug-information Estramustine (Emcyt) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *1981-12-24: Initial FDA approval | ||
| + | ==History of changes in EMA indication== | ||
| + | *1971-09-02: EURD | ||
| + | ==Also known as== | ||
| + | *'''Generic name:''' estramustine phosphate sodium | ||
| + | *'''Brand names:''' Emcyt, Estracit, Estram, Estramin, X-Trant | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| − | [[Category: | + | [[Category:Drugs]] |
| − | [[Category: | + | |
| + | [[Category:Oral medications]] | ||
| + | |||
[[Category:Nitrogen mustards]] | [[Category:Nitrogen mustards]] | ||
| + | |||
[[Category:Prostate cancer medications]] | [[Category:Prostate cancer medications]] | ||
| + | |||
| + | [[Category:FDA approved in 1981]] | ||
| + | [[Category:EMA approved in 1971]] | ||
Revision as of 23:30, 2 September 2023
General information
Class/mechanism: Nornitrogen mustard (similar to mechlorethamine) linked to estradiol. The estradiol component helps the drug to be preferentially delivered to estrogen receptor-positive cells. The mustard component serves as an alkylator and causes DNA crosslinks. Treatment may result in elevated plasma levels of estradiol.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Estramustine (Emcyt) package insert[1]
- Estramustine (Emcyt) patient drug information (Chemocare)[3]
- Estramustine (Emcyt) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1981-12-24: Initial FDA approval
History of changes in EMA indication
- 1971-09-02: EURD
Also known as
- Generic name: estramustine phosphate sodium
- Brand names: Emcyt, Estracit, Estram, Estramin, X-Trant